Literature DB >> 24220766

Are clindamycin and ciprofloxacin appropriate for the empirical treatment of diabetic foot infections?

M G de Vries1, M B Ekkelenkamp, E J G Peters.   

Abstract

The objective of this study was to determine if specific species of microorganisms are associated with severe infection and amputation in patients with a diabetic foot infection and to evaluate the effectiveness of clindamycin and ciprofloxacin in this population. A retrospective cohort study was performed at the University Medical Center Utrecht, The Netherlands, for the period January 1st 2005 to January 1st 2010. Patients with ICD-9 codes 'diabetic foot' were selected from the hospital database. We evaluated the association of Staphylococcus aureus and Gram-negative species (GNS) with severity of infection, number of amputations, and healing rates. No significant association was found between the different microorganisms and infection severity. Coinfections of GNS and S. aureus were significantly associated with amputation compared to infections with only S. aureus [p = 0.016, odds ratio (OR) 4.9, confidence interval (CI) 1.4-16.9]. The empiric antibiotic regimen of clindamycin and ciprofloxacin covered only 85 % of S. aureus and 78 % of GNS diabetic foot infections. In mild diabetic foot infection in the studied population, where methicillin-sensitive S. aureus and streptococci are the most likely pathogens, a beta-lactam antibiotic such as flucloxacillin would likely be more effective than clindamycin. In moderate and severe infections, where GNS as a causative organism cannot be safely excluded, broad-spectrum antibiotic therapy may be more adequate.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24220766     DOI: 10.1007/s10096-013-1977-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  16 in total

1.  Practical guidelines on the management and prevention of the diabetic foot 2011.

Authors:  K Bakker; J Apelqvist; N C Schaper
Journal:  Diabetes Metab Res Rev       Date:  2012-02       Impact factor: 4.876

Review 2.  Expert opinion on the management of infections in the diabetic foot.

Authors:  B A Lipsky; E J G Peters; E Senneville; A R Berendt; J M Embil; L A Lavery; V Urbančič-Rovan; W J Jeffcoate
Journal:  Diabetes Metab Res Rev       Date:  2012-02       Impact factor: 4.876

3.  Prevalence and molecular mechanism of macrolide resistance in beta-haemolytic streptococci in The Netherlands.

Authors:  C C Van Leer Buter; J W Mouton; C H W Klaassen; C M A Handgraaf; S Sunnen; W J G Melchers; P D J Sturm
Journal:  Int J Antimicrob Agents       Date:  2010-03-29       Impact factor: 5.283

4.  Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers.

Authors:  A Sotto; J-L Richard; C Combescure; N Jourdan; S Schuldiner; N Bouziges; J-P Lavigne
Journal:  Diabetologia       Date:  2010-06-23       Impact factor: 10.122

5.  2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; Paul B Cornia; James C Pile; Edgar J G Peters; David G Armstrong; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Michael S Pinzur; Eric Senneville
Journal:  Clin Infect Dis       Date:  2012-06       Impact factor: 9.079

6.  Bacteriological study of diabetic foot infections.

Authors:  Adel Abdulrazak; Zouheir Ibrahim Bitar; Abdullah Ayesh Al-Shamali; Lubna Ahmed Mobasher
Journal:  J Diabetes Complications       Date:  2005 May-Jun       Impact factor: 2.852

7.  Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration.

Authors:  D G Armstrong; L A Lavery; S A Vela; T L Quebedeaux; J G Fleischli
Journal:  Arch Intern Med       Date:  1998-02-09

8.  Bacteriology of diabetic foot.

Authors:  A T El-Tahawy
Journal:  Saudi Med J       Date:  2000-04       Impact factor: 1.484

9.  Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate.

Authors:  Benjamin A Lipsky; Kamal Itani; Carl Norden
Journal:  Clin Infect Dis       Date:  2003-12-09       Impact factor: 9.079

Review 10.  Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment.

Authors:  A R Berendt; E J G Peters; K Bakker; J M Embil; M Eneroth; R J Hinchliffe; W J Jeffcoate; B A Lipsky; E Senneville; J Teh; G D Valk
Journal:  Diabetes Metab Res Rev       Date:  2008 May-Jun       Impact factor: 4.876

View more
  3 in total

1.  Evaluation of the Surgical and Pharmacological Treatment of Diabetic Foot Infection: A Retrospective Study.

Authors:  Adil Hassan Aliakbar; Malath Azeez Alsaadi; Abbas Abd Zaid Barrak
Journal:  Open Access Maced J Med Sci       Date:  2019-05-14

Review 2.  Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice.

Authors:  Laura Armengol Álvarez; Greet Van de Sijpe; Stefanie Desmet; Willem-Jan Metsemakers; Isabel Spriet; Karel Allegaert; Jef Rozenski
Journal:  Antibiotics (Basel)       Date:  2022-05-21

3.  Distribution of Microbes and Drug Susceptibility in Patients with Diabetic Foot Infections in Southwest China.

Authors:  Mingxia Wu; Hang Pan; Weiling Leng; Xiaotian Lei; Liu Chen; Ziwen Liang
Journal:  J Diabetes Res       Date:  2018-08-05       Impact factor: 4.011

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.